STVN (Stevanato Group SpA) ROCE % : 10.02% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Stevanato Group SpA's annualized ROCE % for the quarter that ended in Sep. 2024 was 10.02%.

Stevanato Group SpA ROCE % Historical Data

The historical data trend for Stevanato Group SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SpA ROCE % Chart

Stevanato Group SpA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.31

16.80

19.14

16.31

14.58

Stevanato Group SpA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															15.69	17.02	6.75	6.98	10.02

Stevanato Group SpA ROCE % Calculation

Stevanato Group SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	211.415	/	( ( (1758.155 - 489.939)	+	(2259.081 - 626.377) )	/ 2 )
	=	211.415	/	( (1268.216	+	1632.704)	/ 2 )
	=	211.415	/	1450.46
	=	14.58 %

Stevanato Group SpA's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	188.108	/	( ( (2364.966 - 537.742)	+	(2457.095 - 529.479) )	/ 2 )
	=	188.108	/	( ( 1827.224	+	1927.616 )	/ 2 )
	=	188.108	/	1877.42
	=	10.02 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Stevanato Group SpA (NYSE:STVN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Stevanato Group SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Stevanato Group SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stevanato Group SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SpA (NYSE:STVN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

87N:Germany

Address

Via Molinella 17, Piombino Dese, Padua, ITA, 35017

Website

https://www.stevanatogroup.com

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.